Pancreatic Cancer Cell Genetics and Signaling Response to Treatment Correlate with Efficacy of Gemcitabine-Based Molecular Targeting Strategies

被引：0

作者：

Bryan Holcomb

Michele T. Yip-Schneider

Jesus M. Matos

Jennifer Dixon

Jason Kennard

Julie Mahomed

Rajasubramaniam Shanmugam

Judith Sebolt-Leopold

C. Max Schmidt

机构：

[1] Indiana University School of Medicine,Department of Surgery

[2] Indiana University School of Medicine,Departments of Biochemistry/Molecular Biology

[3] Indiana University School of Medicine,Walther Oncology Center

[4] Indiana University Cancer Center,Department of Hematology and Oncology

[5] Richard L. Roudebush VA Medical Center,undefined

[6] Indiana University School of Medicine,undefined

[7] Pfizer,undefined

[8] Inc.,undefined

来源：

Journal of Gastrointestinal Surgery | 2008年 / 12卷

关键词：

Pancreatic cancer; NF-κB; PI3 kinase; MAP kinase; Gemcitabine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：288 / 296

页数：8

共 50 条

[21] Meta-Analysis of Randomized Trials Evaluation of Benefit of Gemcitabine-Based Molecular Targeted Therapy for Inoperable Pancreatic Cancer
Cao, Yunfei
Wu, Liucheng
Tan, Aihua
Liu, Lidan
Gao, Feng
PANCREAS, 2010, 39 (02) : 253 - 255
[22] Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer
Colloca, Giuseppe
Venturino, Antonella
Guarneri, Domenico
CLINICAL COLORECTAL CANCER, 2016, 15 (03) : 264 - 276
[23] Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies
Regiba, Soukaina
Bigand, Christelle
Parmentier, Celine
Hajri, Amor
NEOPLASIA, 2009, 11 (07): : 637 - 650
[24] MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
Lu, Huimin
Lu, Shan
Yang, Dujiang
Zhang, Ling
Ye, Jun
Li, Mao
Hu, Weiming
BIOSCIENCE REPORTS, 2019, 39
[25] A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
Kaissis, Georgios
Ziegelmayer, Sebastian
Lohoefer, Fabian
Steiger, Katja
Alguel, Hana
Muckenhuber, Alexander
Yen, Hsi-Yu
Rummeny, Ernst
Friess, Helmut
Schmid, Roland
Weichert, Wilko
Siveke, Jens T.
Braren, Rickmer
PLOS ONE, 2019, 14 (10):
[26] Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy
Lautenschlaeger, S.
Dumke, C.
Exeli, L.
Hauswald, H.
Engenhart-Cabillic, R.
Eberle, F.
STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (11) : 982 - 991
[27] Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy
S. Lautenschlaeger
C. Dumke
L. Exeli
H. Hauswald
R. Engenhart-Cabillic
F. Eberle
Strahlentherapie und Onkologie, 2023, 199 : 982 - 991
[28] Meta-analysis of the efficacy between gemcit-abine-alone and gemcitabine-based chemotherapy applied to advanced pancreatic cancer
宋堃
ChinaMedicalAbstracts(Surgery), 2012, 21 (01) : 50 - 50
[29] Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations
Faerber, Benedikt
Lapshyna, Olga
Kuenstner, Axel
Kohl, Michael
Sauer, Thorben
Bichmann, Kira
Heckelmann, Benjamin
Watzelt, Jessica
Honselmann, Kim
Bolm, Louisa
ten Winkel, Meike
Busch, Hauke
Ungefroren, Hendrik
Keck, Tobias
Gemoll, Timo
Wellner, Ulrich F.
Braun, Ruediger
FRONTIERS IN ONCOLOGY, 2023, 13
[30] Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
Chung, Kwang Hyun
Ryu, Ji Kon
Son, Jun Hyuk
Lee, Jae Woo
Jang, Dong Kee
Lee, Sang Hyub
Kim, Yong-Tae
GUT AND LIVER, 2017, 11 (02) : 298 - 305

← 1 2 3 4 5 →